A side letter agreement between Tempus AI, Pathos AI, and Bristol Myers Squibb restricts Tempus AI from licensing its neurology records to other parties for a specified period.

Overview Debates Related claims Topics Sources

The strategic agreements mark Pathos AI's expansion from oncology into neurological conditions, beginning with Alzheimer's disease treatments.

Pathos AI will apply its Foundry platform to Tempus AI's neurological dataset to track patient outcomes and speed research into Alzheimer's disease biology.

Pathos AI agreed to license up to 500,000 de-identified patient records for Alzheimer's or neurological conditions from Tempus AI under a five-year agreement worth up to $55 million, at 100,000 records per year.

Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

Early Alzheimer's symptoms such as hearing impairment can reduce engagement in physical activity, triggering accelerated cognitive and memory decline.

A UK study of 1,139 people over age 50 found that moderate to vigorous physical activity reduced dementia risk by 34% to 50% over eight to ten years.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Brain health benefits against Alzheimer's tau protein accumulation appeared at 3,000 steps daily, with an optimal protective plateau between 5,000 and 7,500 steps daily.

A study tracking almost 300 older adults found that physical activity did not reduce toxic amyloid plaques, but reduced signs of dementia by almost half in more active participants.

In older adults with early brain signs of Alzheimer's, physical activity reduced the accumulation of misfolded tau proteins in specific brain areas over nine to 11 years, according to a study tracking participants with pedometers.

A 2022 UK study tracking 78,430 people for seven years using wrist accelerometers found a 25% reduction in dementia risk at 3,800 daily steps, rising to 50% at 9,800 steps.

Cardiovascular and stroke risk factors including elevated cholesterol, poor sleep, high blood pressure, and diabetes increase dementia risk alongside physical inactivity.

In an ongoing Phase 1/2a trial in healthy volunteers, Arrowhead Pharmaceuticals' experimental RNA interference therapeutic ARO-MAPT administered via subcutaneous injection reduced cerebrospinal fluid total tau protein by an average of 73% at day 105 in the highest dose cohort receiving 12.8 mg/kg on days 1 and 15, with maximum individual reduction reaching 85%.

The Phase 1/2a trial of ARO-MAPT aims to enroll 112 total participants, expanding from healthy volunteers into patients with early Alzheimer's disease receiving up to five subcutaneous injections, with further data updates expected in 2027.

Arrowhead Pharmaceuticals reported that ARO-MAPT was generally well tolerated in healthy volunteers, with no serious adverse events, deaths, or toxicity-related study dropouts, and mild reported side effects including injection site reactions, vessel puncture bruising, respiratory infections, and headaches.

Healthy volunteers receiving subcutaneous ARO-MAPT doses of 2.1 mg/kg and 6.4 mg/kg on days 1, 8, and 15 in the Phase 1/2a trial achieved average cerebrospinal fluid tau reductions of 40% and 69% respectively at day 105.

ARO-MAPT is designed to silence expression of the microtubule-associated protein tau (MAPT) gene in the central nervous system, targeting pathological tau protein aggregation implicated in Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy.

Stifel analyst James Condulis noted in an October 14, 2026 report that Arrowhead Pharmaceuticals' subcutaneous drug delivery across the blood-brain barrier looks compelling and arguably better than competing central nervous system delivery platforms.

Arrowhead Pharmaceuticals is in discussions with health regulators to initiate clinical trials evaluating ARO-MAPT in patients with MAPT-associated frontotemporal dementia and progressive supranuclear palsy.

Arrowhead Pharmaceuticals stated that the Phase 1/2a ARO-MAPT trial results provide clinical validation for its drug platform to deliver subcutaneous RNA-modulating therapeutics across the blood-brain barrier into the central nervous system.